Starling Oncology, Inc. (DFPH) Return on equity 2020–2024
Starling Oncology, Inc. (DFPH) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-1801.7%FY2024 · since FY2020: -51.0% → -1801.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -1801.7% | -1656.0 pp |
| FY2023 | -145.7% | -145.8 pp |
| FY2022 | 0.1% | +10.6 pp |
| FY2021 | -10.5% | +40.5 pp |
| FY2020 | -51.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More DFPH financial trends
DFPH RevenueDFPH Net incomeDFPH Net marginDFPH Gross profitDFPH Gross marginDFPH Operating incomeDFPH Operating marginDFPH Operating cash flowDFPH Free cash flowDFPH Capital expendituresDFPH Stock buybacksDFPH Dividends paidDFPH Total assetsDFPH Total liabilitiesDFPH Shareholders’ equityDFPH overview →